Axsome Therapeutics (NASDAQ:AXSM), a biopharmaceutical company at the forefront of treating central nervous system (CNS) disorders, today announced that SYMBRAVO® (meloxicam and rizatriptan) is now available by prescription in the United States.
This novel medication is indicated for the acute treatment of migraine with or without aura in adults.
SYMBRAVO offers a new, multi-mechanistic approach to migraine treatment, targeting multiple brain pathways implicated in a migraine attack.
Clinical data demonstrate that SYMBRAVO rapidly achieves migraine pain freedom and restores patients to normal functioning within two hours compared to placebo.
Importantly, some patients experienced lasting pain freedom sustained from two to 24 hours after a single dose.
Migraine is a severely debilitating neurological condition marked by recurrent attacks of pulsating, often intense and incapacitating head pain, frequently accompanied by nausea, sensitivity to light (photophobia), and/or sensitivity to sound (phonophobia).
Affecting approximately 40 million people in the U.S., migraine was identified as the second leading cause of all disability worldwide in the Global Burden of Disease study in 2019.
A recent survey highlighted the significant unmet need in migraine treatment, revealing that 63% of over 1700 migraine patients were dissatisfied with their current treatment plan.
The availability of SYMBRAVO offers a promising new option for adults seeking effective and rapid relief from acute migraine symptoms.